5-11-2023, 23:00

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

[img]http://phpstack-911252-3168991.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=8f380244-5b9d-4565-86e8-e3
Globe Newswire5-11-2023, 23:00
15-10-2023, 20:03

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
Globe Newswire15-10-2023, 20:03
28-06-2023, 16:00

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
Globe Newswire28-06-2023, 16:00
25-06-2023, 20:00

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Globe Newswire25-06-2023, 20:00